Boston, Aug. 20, 2025 (GLOBE NEWSWIRE) — According to the latest study from BCC Research, the “Genome Editing: Technologies and Global Markets” is projected to grow from $10.8 billion in 2025 to $23.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.9% during the forecast period of 2025 to 2030.
This report offers a detailed analysis of the global genome editing market, highlighting technologies such as CRISPR-Cas, TALEN, and ZFN. It examines their applications in drug development, plant breeding, diagnostics, and clinical therapy across biopharmaceutical, agricultural biotech, and research sectors. The study covers regional trends in North America, Europe, Asia-Pacific, and the Rest of the World, and evaluates market dynamics including drivers, challenges, opportunities, and ESG developments. It also provides insights into clinical trials, patents, emerging technologies, and profiles of leading companies within a competitive landscape.
This report is especially relevant today due to the rising global incidence of genetic disorders, cancer, and rare diseases, which is driving the rapid adoption of genome editing technologies. Simultaneously, the agricultural sector is leveraging these tools to tackle challenges related to food security, climate resilience, and nutritional improvement. With substantial investments from governments and private entities fueling R&D, this is a pivotal moment to assess the market’s potential, technological advancements, and competitive dynamics.
The factors driving the market’s growth include:
New Genome-Editing Technologies and Applications: Innovations like CRISPR-Cas9, TALENs, and ZFNs have made genome editing more precise, affordable, and versatile. These tools are being used in medicine, agriculture, and biotechnology, expanding the scope and commercial potential of genome editing.
Prevalence of Genetic Disorders: Millions of people worldwide suffer from genetic diseases, many of which have limited treatment options. Genome editing offers the possibility of correcting these disorders at the DNA level, driving demand for therapeutic solutions.
Increasing Government and Private Funding: Governments and private investors are funding genome editing R&D. This financial support accelerates innovation, clinical trials, and commercialization, boosting market growth.
Request a sample copy of the global market for genome editing report.
Report Synopsis
| Report Metric | Details |
| Base year considered |